Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity
2023
Borrego Écija, Sergi | Pérez Millan, Agnès | Antonell, Anna | Fort Aznar, Laura | Kaya Tilki, Elif | León Halcón, Alberto | Vitorica Ferrández, Francisco Javier | Venero Recio, José Luis | Boza Serrano, Antonio | Universidad de Sevilla. Departamento de Bioquímica y Biología Molecular | Instituto de Salud Carlos III | Generalitat de Catalunya | Ministerio de Ciencia e Innovación (MICIN). España | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER)
INTRODUCTION Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate Gal-3 levels in patients with FTD and assess its diagnostic potential. METHODS We examined Gal-3 levels in brain, serum, and cerebrospinal fluid (CSF) samples of patients with FTD and controls. Multiple linear regressions between Gal-3 levels and other FTD markers were explored. RESULTS Gal-3 levels were increased significantly in patients with FTD, mainly across brain tissue and CSF, compared to controls. Remarkably, Gal-3 levels were higher in cases with tau pathology than TAR-DNA Binding Protein 43 (TDP-43) pathology. Only MAPT mutation carriers displayed increased Gal-3 levels in CSF samples, which correlated with total tau and 14-3-3. DISCUSSION Our findings underscore the potential of Gal-3 as a diagnostic marker for FTD, particularly in MAPT cases, and highlights the relation of Gal-3 with neuronal injury markers.
显示更多 [+] 显示较少 [-]Instituto de Salud Carlos III de España y fondos europeos FEDER - PI20/0448, PI19/00449, PI18/01556, PI21/00914
显示更多 [+] 显示较少 [-]Generalitat de Cataluña - SGR2021- 01126
显示更多 [+] 显示较少 [-]Ministerio de Ciencia e Innovación de España y fondos europeos /FEDER/UE - PID2021-124096OB-I00
显示更多 [+] 显示较少 [-]